UroGen Pharma Ltd. Announces \$250 Million Loan Facility – Key Details for Investors

Summary of the Material Event

UroGen Pharma Ltd. (NASDAQ: URGN) has entered into a significant new financing arrangement. On February 26, 2026, the company and its subsidiary, UroGen Pharma, Inc., executed a loan agreement with BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and BioPharma Credit PLC (serving as collateral agent for the lenders). This agreement provides UroGen with an aggregate principal amount of up to \$250 million in term loans, to be advanced in two separate tranches.

Key Details of the Loan Agreement

• Total Principal: Up to \$250 million, split into two tranches:
  • Tranche A: \$125 million, funded on the effective date of the Loan Agreement
  • Tranche B: \$125 million, available for future drawdown
• Interest Rate: Fixed at 8.25% per annum, payable quarterly in arrears.
• Repayment Terms: Principal repayments will occur in four equal quarterly installments, starting in Q1 2030.
• Prepayment Options: The borrower may elect to prepay the loans in full prior to maturity, subject to the payment of an “Exit Fee” and, if before the first anniversary of each tranche’s closing, a “Makewhole Amount” (the sum of all interest that would have accrued through the first anniversary).
• Fees:
  • Funding Fee: 1.5% of each tranche’s committed amount, payable on the respective closing dates.
  • Exit Fee: 1% of the principal amount repaid, applicable to all principal repayments, including scheduled, accelerated, or voluntary prepayments.
  • Makewhole Amount: If loans are repaid before the first anniversary of the relevant closing date, all interest that would have accrued through that date is payable in full.
• Use of Proceeds: The funds may be used for refinancing existing debt (specifically up to \$125 million of outstanding principal) and for general corporate and working capital purposes.
• Security and Guarantees: The loans are secured by substantially all tangible and intangible assets of UroGen Pharma Ltd. and its subsidiary, including intellectual property (with standard exceptions). The parent company guarantee is subject to Israeli legal limitations.
• Mandatory Prepayment: Required upon a change of control or prior to certain prepayments/redemptions of permitted convertible debt (with exceptions for refinancing and equity conversion/exchange).
• Covenants:
  • Affirmative covenants (e.g., information delivery, insurance maintenance, notice requirements)
  • Restrictive covenants (e.g., limitations on asset sales, changes to material agreements, incurrence of new debt, granting of new liens, dividend payments, and payments on subordinated debt)
  • No financial covenants (i.e., no requirements relating to financial ratios or minimum liquidity)
• Events of Default: Includes non-payment, breach of covenants, material adverse change, attachment or restraint of assets, bankruptcy/insolvency, cross-default, judgment default, misrepresentation, and invalidity of loan documents.
• Remedies: Upon an event of default, the lenders may accelerate all loan obligations (principal, interest, exit fee, makewhole amount).

Why This Matters for Shareholders

• Significant Capital Injection: The \$250 million facility provides UroGen with substantial liquidity to refinance existing debt and fund ongoing operations and growth initiatives.
• Interest Rate and Fee Impact: The relatively high fixed interest rate (8.25%) and associated fees may increase the company’s cost of capital.
• Leverage and Security: The secured nature of the loan and broad collateral package, including intellectual property, means that in a default scenario, lenders would have claims to core assets, potentially increasing risk for equity holders.
• Potential for Early Repayment Costs: If the company repays early, substantial makewhole and exit fees could impact cash flow and earnings.
• Share Price Sensitivity: The announcement of a large secured loan may be seen as positive (addressing liquidity/refinancing needs and reducing near-term default risk), but the terms (interest, fees, and asset pledges) could be viewed as a sign of higher risk or limited financing alternatives. This could drive share price volatility as investors assess the company’s financial position and future prospects.
• No Immediate Equity Dilution: The financing is debt-based without equity warrants or direct dilution. However, the restrictive covenants could limit future flexibility regarding dividends, share repurchases, or new financings.
• Change of Control Provision: Any sale or change of control would trigger mandatory prepayment, which could affect M&A valuations or strategic options.

Conclusion

The secured \$250 million loan agreement is a major development for UroGen Pharma Ltd. It provides liquidity and financial runway, but at a meaningful cost and with significant restrictions. Investors should closely monitor the company’s use of proceeds, compliance with covenants, and overall strategy given the new debt burden and security package. This event is likely to be price-sensitive and may drive share price movement as the market digests the implications for risk, growth, and financial flexibility.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should consult their own advisors and review company filings and press releases before making investment decisions. The author is not responsible for any investment actions taken based on this content.

View UroGen Pharma Ltd. Historical chart here